Teva, along with drug distributors Baxter International and McKesson, allegedly marketed propofol in oversized vials, knowing that physicians and nurses would be tempted to re-use the vials and potentially expose patients to bloodborne diseases. Robert Eglet, a lawyer for the colonoscopy patients who developed hepatitis after receiving propofol, said responsible drug companies should not prioritize profits over patient safety.
Teva faces almost 300 lawsuits stemming from a hepatitis C outbreak in southern Nevada three year ago. The trial of the first case against Teva and Baxter resulted in a verdict of more than $500 million against the drug manufacturers.
Related Articles on Anesthesia:
Patient Education Discharge Planning Makes Two Day Discharge After Arthroplasty Possible
Effectiveness of Placebos May Depend on Cannabinoid Pathways
Chicago Anesthesiologist Develops Injections to Treat Post-Traumatic Stress Disorder
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
